Advanced/Recurrent Ovarian Cancer
Oncology·MeSH: Ovarian Neoplasms
Prevalence
24.0 / 100K
Incidence
10.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| saruparib | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Advanced/Recurrent Ovarian Cancer?
BioSniper tracks 1 drug in development for Advanced/Recurrent Ovarian Cancer across 1 company.
How many clinical trials target Advanced/Recurrent Ovarian Cancer?
There are 1 clinical trial targeting Advanced/Recurrent Ovarian Cancer tracked by BioSniper.
What is the prevalence of Advanced/Recurrent Ovarian Cancer?
The estimated prevalence of Advanced/Recurrent Ovarian Cancer is approximately 24.0 per 100,000 population.
Deep-dive into Advanced/Recurrent Ovarian Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis